Schiff Nutrition International, Inc. develops, manufactures, markets, and distributes vitamins, nutritional supplements, and nutrition bars in the United States and internationally. The company offers a line of specialty supplements, vitamins, and minerals under the Schiff brand. Its specialty supplements include joint care products under the Move Free brand and glucosamine products; omega-3 products under the MegaRed brand; a line of probiotic digestive health products under the Digestive Advantage and Sustenex brands; immune support products under the Airborne brand; and various other specialty supplements. The company’s specialty supplement products also comprise omega-3 products, such as...
2002 South 5070 West
Salt Lake City, UT 84104-4726
Founded in 1996
Schiff Nutrition International Inc. Announces Board Changes; Announces Amendment to Bylaws
Dec 15 12
On December 15, 2012, in accordance with the Merger Agreement and the Schiff Nutrition International Inc.’s bylaws, immediately following the Offer Acceptance Time, (i) Tarang P. Amin, Ronald L. Corey, Roger H. Kimmel, George F. Lengvari, William E. McGlashan, Jr., Brian T. Swette, Eric Weider and Richard G. Wolford resigned from the Board of Directors of the Company and each committee thereof of which such person was a member and (ii) the continuing members of the Board appointed John Brennan, Markus Hartmann, Frederic Larmuseau, William Mordan, Elliott Penner, Elizabeth Richardson and Kelly Slavitt to the Board as directors of the company to fill the vacancies on the Board, in each case effective as of the Offer Acceptance Time. In addition, upon the resignation of Messrs. Corey and Wolford from their positions on the Audit Committee of the Board, the Board appointed Michael Hyatt and Matthew T. Hobart to fill the vacancies on that committee. On December 17, 2012, in accordance with the Merger Agreement and the company’s bylaws, Michael Hyatt, Matthew T. Hobart and Eugene B. Jones resigned from the Board, effective as of the Effective Time. Messrs. Brennan, Hartmann, Larmuseau and Penner served as directors of Purchaser, and in accordance with Merger Agreement, following the Effective Time, shall continue to serve as directors on the Board, effective as of the Effective Time.
On December 17, 2012, in connection with the completion of the Merger, the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws of the company were each further amended and restated in accordance with the terms of the Merger Agreement.
Reckitt Benckiser Group plc, Schiff Nutrition International Inc. - M&A Call
Nov 15 12
To acquire all of the outstanding shares of Schiff Nutrition International, Inc.
Schiff Nutrition International Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended August 31, 2012; Raises Earnings Guidance for the Fiscal Year of 2013
Sep 18 12
Schiff Nutrition International Inc. reported unaudited consolidated earnings results for the first quarter ended August 31, 2012. For the quarter, the company’s net sales were $85.133 million compared to $58.238 million for the same period a year ago. Income from operations was $12.337 million compared to $7.753 million for the same period a year ago. Income before income taxes was $9.615 million compared to $7.402 million for the same period a year ago. Net income was $6.029 million or $0.20 per diluted share compared to $4.703 million or $0.16 per diluted share for the same period a year ago. Adjusted EBITDA was $17.406 million against $9.637 million a year ago. Net sales increased 46% and adjusted EBITDA increased 81% versus 1 year ago, reflecting progress executing the company's growth strategy to build brands in four key conditions. Brand building, innovation, and customer initiatives continue to drive MegaRed in heart health, Move Free in joint care, Airborne in immune support, and Digestive Advantage in probiotics.
For the full fiscal year of 2013, the company raising its earnings guidance. Now the company expects net sales growth to 43% to 46% from 40% to 43%, operating margin to 14.5% to 16% from 12.5% to 14% and gross profit margin to 49.0% to 51.0% from 48.0% to 50.0% of previous guidance.